4OEVALUATING THE PLACE OF INTERLEUKIN-2 IN THE MANAGEMENT OF METASTATIC RENAL CELL CANCER (MRCC) IN THE ERA OF TARGETED THERAPY

experienced expected toxicities associated with treatment. 8 (5.5%) (Group A) and 2 (5.7%)(Group B) of patients were transferred to critical care for invasive monitoring. 5 (3.4%) patients in the treatment-naive group developed myocarditis vs 3 (8.5%) in the pre-treated group – with one treatment related death in (related to myocarditis). Conclusions: Our results confirm that HD-IL2 remains an effective first-line treatment in well-selected patients with mRCC providing durable complete remissions in over 20% of patients. While cardiac toxicity appears higher in pre-treated patients, HD-IL2 in this setting is effective, tolerable and can produce durable remissions comparable to those seen in the first-line setting. With the introduction of increasing numbers of therapies (including new immune therapies) for the treatment of mRCC it is important to make the best use of all treatments and to combine / sequence therapies to maximise the chance of durable benefits for patients. Disclosure: All authors have declared no conflicts of interest.